Anita Liao
PhD candidate
- Name
- C. Liao MSc
- Telephone
- +31 71 527 5706
- c.liao@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0001-7440-4065
Anita Liao (M.Sc.) is a PhD student at the Division of Drug Discovery & Safety.
I joined the Master’s program of Bio-pharmaceutical science at Leiden University in 2017. My first internship was performed at the division of Drug Discovery and Safety in the lab of Prof. Erik Danen, where I explored the role of the GRHL2 transcription factor in different breast cancer subtypes. To further link basic science into translational medicine, I join the Laboratory of Experimental Urology at Erasmus MC Rotterdam, under supervision of Dr. Wytske M. van Weerden for my second internship. The project is to use next generation androgen receptor antagonist (Apalutamide) to enhance radiosensitivity and improve radiotherapy responses in prostate cancer patients, and it’s under mechanism in DNA repair process.
After obtaining my Master’s degree, I started my PhD at the division of Drug Discovery and Safety at LACDR, at the group of Prof. Erik Danen in 2019. My project is focusing on image-based antibody-mediated tumor immunity. I will establish a high throughput confocal microscopy-based screening method to determine the cytotoxic potential of T-cells recruited by bispecific antibody in 3D tumor spheroids model.
PhD candidate
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Toxicology
- Coban B., Wang Z., Liao C., Beslmüller K., Timmermans M.A.M., Martens J.W.M., Hunscheid J.H.M., Slütter B.A., Zweemer A.J.M., Neubert E. & Danen E.H.J. (2024), GRHL2 suppression of NT5E/CD73 in breast cancer cells modulates CD73-mediated adenosine production and T cell recruitment, iScience 27(5): 109738.
- Liao C., Engelberts P., Ioan-Facsinay A., Klip J.A., Schmidt T., Ruijtenbeek R. & Danen E.H.J. (2024), CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing, Communications Biology 7(1): 983.
- Kortleve D., Hammerl D., Brakel M. van, Wijers R., Roelofs D., Kroese K., Timmermans M.M., Liao C., Huang S., Trapman-Jansen A., Foekens R., Michaux J., Beijer M.T.A. de, Buschow S.I., Demmers J.A., Kok M., Danen E.H.J., Bassani-Sternberg M., Martens J.W.M., Abbott R.J.M. & Debets R. (2024), TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer, Cancer Discovery : 1-21.
- Dang H., Harryvan T.J., Liao C.Y., Danen E.H.J., Spalburg V.N.L.N., Kielbasa S.M., Mei H., Goeman J.J., Jonge-Muller E.S. de, Janson S.G.T., Reijden J.J. van der, Crobach S., Hardwick J.C.H., Boonstra J.J., Miranda N.F.C.C. de & Hawinkels L.J.A.C. (2023), Cancer-associated fibroblasts are key determinants of cancer cell invasion in the earliest stage of colorectal cancer, Cellular and Molecular Gastroenterology and Hepatology 16(1): 107-131.
- Dang H., Harrijvan T.J., Liao C., Danen E.H.J., Miranda N.F. de, Hardwick J., Boonstra J. & Hawinkels L. (2022), Cancer-associated fibroblasts in T1 colorectal cancer promote matrix remodeling and tumor organoid expansion, Gastroenterology 162(7): S323.